If you're running an opioid treatment program or office-based MAT practice, you already know that billing for MAT services in opioid treatment programs is nothing like standard behavioral health billing. Methadone claims get denied because staff bill per dose instead of per week. Buprenorphine visits trigger audits when E&M codes don't match documentation. Vivitrol injections sit in limbo waiting for prior authorization while your revenue cycle bleeds cash.
The root cause? Most billing teams treat methadone, buprenorphine, and naltrexone as interchangeable MAT services. They're not. Each medication operates under a completely different billing model, and conflating them guarantees denials, clawbacks, and compliance headaches.
This guide breaks down exactly how to bill each MAT medication correctly, what Medicaid and commercial payers expect, where 42 CFR Part 2 intersects with your claims, and the specific errors that cost OTPs and office-based programs thousands in lost revenue every month.
Why MAT Billing Is Structurally Different from Standard SUD Billing
Standard substance use disorder billing typically follows a fee-for-service model. You provide a group therapy session, you bill for that session. You conduct an assessment, you bill for the assessment. MAT billing doesn't work that way.
Methadone in an OTP setting bills as a bundled weekly service under HCPCS code H0020. That bundle includes the medication, daily dosing observation, and basic clinical monitoring. You don't bill per dose. You don't bill per visit. You bill once per week, regardless of how many times the patient showed up.
Buprenorphine in office-based settings follows a hybrid model. You're billing for physician time and medical decision-making using E&M codes (99213, 99214), not for the medication itself when it's prescribed as a take-home. The medication gets billed through pharmacy claims. Your clinic bills for the visit where prescribing decisions and monitoring occur.
Naltrexone injectable (Vivitrol) uses CPT 96372 for the administration of the injection itself, plus the drug cost billed separately with an NDC code. This is a procedure-based billing model, not a visit-based or bundled model.
These three structures are fundamentally incompatible. Billing staff trained on one model will make costly errors when handling the others. That's why specialized MAT billing infrastructure matters more than generic behavioral health billing experience.
Methadone OTP Billing: How H0020 Works as a Weekly Bundled Service
HCPCS code H0020 is the foundation of methadone OTP billing. It represents one week of methadone treatment, which includes the medication itself, daily observed dosing, and nursing or clinical monitoring required by federal OTP regulations.
Here's what's included in the H0020 bundle: the methadone doses administered that week, nursing oversight during dosing, basic vitals monitoring, and dose adjustments made by clinical staff. You cannot bill separately for these components. They're part of the weekly rate.
What you can bill separately: individual counseling sessions (typically H0004 or state-specific codes), group counseling (H0005), comprehensive assessments (H0001), and urinalysis/drug screens (80305 or similar). These services are not included in the H0020 bundle and should be billed as standalone line items when provided.
The critical error most OTPs make: billing H0020 for every day the patient shows up. If a patient doses Monday through Saturday, that's still one unit of H0020 for the week, not six units. The bundle is time-based (weekly), not visit-based.
Before you can bill H0020 at all, your program must hold SAMHSA certification as an Opioid Treatment Program under 42 CFR Part 8. Medicaid and commercial payers will reject claims from non-certified providers. This certification is separate from state licensure and requires compliance with federal dosing, diversion control, and clinical staffing standards.
One more complication: some state Medicaid programs reimburse H0020 as a flat weekly rate, while others use a tiered structure based on the number of doses actually administered that week. Know your state's Medicaid plan rules before you submit your first claim. Programs expanding into states like Texas or Pennsylvania need to verify these structures upfront.
Buprenorphine Office-Based Billing: Combining E&M Codes with Prescription Management
Office-based buprenorphine treatment (often called OBOT or office-based opioid treatment) bills completely differently from methadone OTPs. You're not billing for the medication directly. You're billing for the physician or advanced practice provider's time, evaluation, and medical management.
The primary codes are E&M visit codes: 99213 for established patient visits of moderate complexity, and 99214 for visits requiring more extensive evaluation and medical decision-making. These are the same codes used for any outpatient physician visit, but the documentation must support the level billed.
For induction visits, where a patient is starting buprenorphine for the first time or restarting after a gap, you'll typically bill a higher-level E&M code (99214 or sometimes 99215) because the medical decision-making is more complex. You're assessing withdrawal symptoms, determining appropriate dosing, educating the patient on medication use, and establishing a monitoring plan.
For maintenance visits, where the patient is stable on buprenorphine and you're primarily monitoring adherence and adjusting as needed, 99213 is often appropriate. But don't automatically downcode every maintenance visit. If the patient presents with new complications, polysubstance use concerns, or requires significant counseling on medication adherence, 99214 may be justified.
The medication itself is billed through the pharmacy when the patient fills their prescription. Your clinic doesn't bill for the buprenorphine product unless you're dispensing directly, which most office-based programs don't do. The pharmacy submits the drug claim. Your clinic submits the visit claim.
Common error: billing an E&M code and a separate "medication management" add-on code for the same visit. The medication management is already included in the E&M code's medical decision-making component. Double-billing this way triggers audits and clawbacks.
Another error: insufficient documentation to support the E&M level billed. If you bill 99214 but your note only documents "patient doing well, refill provided," you're setting yourself up for a denial or recoupment. The note must reflect the complexity of the medical decision-making and time spent.
Naltrexone/Vivitrol Billing: CPT 96372 and the NDC Code Requirement
Injectable naltrexone (Vivitrol) follows a procedure-based billing model. You bill CPT code 96372 for the therapeutic, prophylactic, or diagnostic injection administered subcutaneously or intramuscularly. Vivitrol is an intramuscular injection, so 96372 is the correct code.
But 96372 alone isn't enough. You must also bill the drug itself using the appropriate NDC (National Drug Code) and the number of units administered. Most payers require the NDC on the claim, and missing it is one of the fastest ways to get a Vivitrol claim denied.
The drug cost is significant. Vivitrol typically costs between $1,200 and $1,800 per dose, and most payers require prior authorization before they'll approve coverage. That prior auth process can take days or weeks, so you need to initiate it well before the patient's scheduled injection date.
Prior authorization requirements vary by payer. Commercial insurance often requires documentation that the patient has failed other forms of MAT (like oral naltrexone or buprenorphine) before approving Vivitrol. Medicaid programs may have different criteria, and some state Medicaid plans don't cover Vivitrol at all for certain populations.
Billing tip: submit the prior authorization request immediately after the patient's initial evaluation, not the day before their first injection. Build prior auth lead time into your clinical workflow, or you'll end up with patients scheduled for injections that aren't approved yet.
Another consideration: some payers reimburse the drug cost separately from the administration fee (96372), while others bundle them. Know how your top payers handle this split before you submit claims, or you'll underbill and leave money on the table.
How Medicaid Reimburses MAT vs. Commercial Insurance
Medicaid and commercial insurance handle MAT reimbursement in fundamentally different ways, and treating them the same is a recipe for denials.
Medicaid typically reimburses methadone OTP services (H0020) at a flat weekly rate or a tiered rate based on dosing frequency. The rate is set by the state Medicaid plan and doesn't vary by patient acuity or additional services provided within the bundle. Counseling and assessments are reimbursed separately at state-specific rates.
Commercial insurance may not recognize H0020 at all. Some commercial payers require you to bill methadone services using CPT codes instead of HCPCS codes, or they may require prior authorization for ongoing methadone treatment beyond an initial stabilization period.
For buprenorphine, Medicaid generally covers E&M visits without prior authorization as long as the prescribing provider is enrolled in Medicaid and the patient meets medical necessity criteria. But some state Medicaid programs cap the number of buprenorphine visits per month or require periodic re-authorization.
Commercial payers often require prior authorization for buprenorphine prescriptions themselves (billed through the pharmacy), but not necessarily for the office visits. However, some commercial plans have moved to "step therapy" requirements where patients must try other treatments before buprenorphine is covered.
Vivitrol prior authorization is nearly universal across both Medicaid and commercial payers, but the criteria differ. Medicaid may prioritize cost-effectiveness and require failure of oral naltrexone first. Commercial payers may focus on adherence history and require documentation that the patient is likely to be non-compliant with daily oral medications.
The takeaway: you cannot use a one-size-fits-all billing approach for MAT services. Your billing team needs payer-specific workflows for each medication type, and those workflows must account for state Medicaid variations. Programs operating in multiple states face exponentially more complexity, which is why understanding payer-specific billing requirements is critical.
42 CFR Part 2 Compliance and Billing: What It Means for Claim Submission
42 CFR Part 2 is the federal regulation that protects the confidentiality of substance use disorder treatment records. It's stricter than HIPAA, and it directly impacts how you bill for MAT services.
Here's the core issue: to submit a claim to insurance, you must disclose that the patient received SUD treatment. That disclosure requires patient consent under 42 CFR Part 2. Without a compliant consent form, you cannot bill insurance for MAT services.
The consent form must be specific. It needs to name the payer (or category of payers), describe what information will be disclosed (diagnosis, treatment dates, services provided), state the purpose of the disclosure (payment), and include an expiration date. A generic HIPAA consent form does not satisfy 42 CFR Part 2 requirements.
Most programs get this wrong in one of two ways. First, they use a HIPAA-only consent and assume it covers billing. It doesn't. Second, they obtain a 42 CFR Part 2 consent but fail to update it when the patient changes insurance or when the consent expires.
When you submit a MAT claim, you're disclosing SUD treatment to the payer. If you don't have valid consent on file, you're violating federal law. If an audit reveals missing or expired consents, you could face fines, be required to return payments, and lose your ability to bill certain payers.
Coordination of benefits adds another layer. If a patient has primary and secondary insurance, you need consent to disclose to both payers. If you bill the secondary payer without consent, you're non-compliant even if you had consent for the primary.
Third-party billing companies must also comply with 42 CFR Part 2. If you outsource billing, your billing company is a "business associate" under HIPAA, but they're also a recipient of Part 2-protected information. Your contract with them must include Part 2-specific language, not just a standard BAA.
Recent updates to 42 CFR Part 2 (aligned with provisions in the SUPPORT Act) have made some aspects of billing easier, but the core consent requirement remains. Don't assume you can bill without it.
The Most Common MAT Billing Errors That Generate Denials and Clawbacks
Here are the specific errors that cost OTPs and office-based MAT programs the most money, based on real-world billing data and audit results.
Billing methadone per dose instead of per week. This is the number one error in OTP billing. Staff see a patient dose six times in a week and submit six units of H0020. The claim gets denied or paid incorrectly, and the subsequent audit triggers a clawback. Always bill H0020 once per week, regardless of dosing frequency.
Missing NDC codes on injectable naltrexone claims. If you bill CPT 96372 for a Vivitrol injection but don't include the NDC code and units for the drug itself, the claim will be denied or paid at a drastically reduced rate. Most practice management systems don't automatically populate NDC codes, so this requires manual entry or custom billing rules.
E&M level mismatches on buprenorphine visits. Billing 99214 for every buprenorphine visit when your documentation only supports 99213 is a fast track to an audit. Payers use algorithms to flag providers who consistently bill higher-level codes without corresponding documentation. Make sure your clinical notes justify the level billed.
Failing to document medical necessity for continued MAT. Payers expect ongoing documentation that MAT is medically necessary. If your notes don't explain why the patient continues to need methadone, buprenorphine, or naltrexone, the payer can deny claims for lack of medical necessity. This is especially common in maintenance-phase billing where providers get complacent with documentation.
Billing counseling services that are included in the H0020 bundle. Some OTPs try to bill individual counseling separately when the counseling was provided during the dosing visit and didn't meet the threshold for a standalone service. If the counseling was brief and directly related to dosing compliance, it's part of the bundle. If it was a separate, scheduled 30-minute or 60-minute individual session, it can be billed separately.
Not obtaining prior authorization for Vivitrol. This seems obvious, but it's shockingly common. Clinics schedule Vivitrol injections, administer them, and then submit claims without prior auth. The claims are denied, and the clinic is stuck with the cost of a $1,500 medication.
Expired or missing 42 CFR Part 2 consents. As discussed earlier, billing without valid consent is a compliance violation. But it's also a revenue problem, because claims submitted without proper consent can be denied retroactively if discovered during an audit.
Avoiding these errors requires more than just training your billing staff. It requires system-level controls, automated checks in your billing software, and regular audits of your own claims before payers audit you. Many programs find that efficient billing infrastructure built specifically for MAT services pays for itself by preventing these costly mistakes.
Frequently Asked Questions About Billing for MAT Services
Can you bill counseling separately from methadone in an OTP? Yes, but only if the counseling is a distinct service provided outside the scope of the H0020 bundle. Individual counseling sessions (H0004) and group counseling (H0005) that are scheduled separately and meet the time and documentation requirements can be billed in addition to the weekly methadone bundle.
What happens if a patient misses a methadone dose during the week? You still bill one unit of H0020 for the week. The bundle is based on the week of treatment, not the number of doses administered. However, some state Medicaid programs use tiered reimbursement where the rate changes based on the number of doses given, so check your state's specific rules.
How do you handle prior authorization for buprenorphine? Prior auth requirements for buprenorphine vary by payer. Most Medicaid programs don't require prior auth for the office visits (E&M codes), but some require it for the medication itself, which is handled by the pharmacy. For commercial insurance, check each payer's policy. Some require prior auth for both the visits and the medication, especially for brand-name buprenorphine products.
What are the telehealth MAT billing rules post-2026? During the COVID-19 public health emergency, telehealth rules for MAT were significantly relaxed, allowing buprenorphine induction via telehealth and methadone take-homes without in-person visits. Many of these flexibilities have been extended through 2024, but the rules are set to change. As of now, the DEA and SAMHSA are working on permanent telehealth rules for MAT. Expect that buprenorphine prescribing via telehealth will likely remain permissible with some guardrails, but methadone OTP rules will likely return to requiring more in-person contact. Monitor federal guidance closely, as billing codes and reimbursement rules will follow regulatory changes.
Get Your MAT Billing Right from Day One
Billing for MAT services across methadone, buprenorphine, and naltrexone programs requires specialized knowledge that most general behavioral health billing teams simply don't have. The bundled weekly structure of H0020, the E&M coding nuances for buprenorphine, the NDC requirements for Vivitrol, the state-by-state Medicaid variations, and the 42 CFR Part 2 compliance layer all combine to create a billing environment where even small errors compound into serious revenue loss.
If you're running an OTP or office-based MAT program and your billing isn't optimized for these specific medication models, you're leaving money on the table every single week. Worse, you're exposing your program to compliance risk and audit liability.
ForwardCare MSO provides full-service billing infrastructure built specifically for MAT programs. We handle H0020 bundling, E&M coding for buprenorphine, Vivitrol prior authorizations, state Medicaid variations, and 42 CFR Part 2 compliance so your clinical team can focus on patient care instead of claim denials. Whether you're launching a new MAT program or fixing billing problems in an existing one, we have the systems and expertise to get your claims paid correctly the first time.
Contact ForwardCare today to learn how we can stabilize your MAT billing and maximize your program's revenue.
